<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02476448</url>
  </required_header>
  <id_info>
    <org_study_id>FLA 15-015</org_study_id>
    <nct_id>NCT02476448</nct_id>
  </id_info>
  <brief_title>Evaluation of Ureteral Jets on Cystoscopy</brief_title>
  <acronym>JET</acronym>
  <official_title>Evaluation of Ureteral Jets on Cystoscopy: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cecilia Calvo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates 4 different methods to aid surgeons to visualize ureteral jets on
      cystoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study proposes to test and compare the surgeon's impression/confidence in identifying
      ureteral jets using 3 other methods in contrast to standard diagnostic cystoscopy: 1)
      cystoscopy with Dextrose 10% solution, 2) cystoscopy with phenazopyridine and 3) IV sodium
      fluorescein 4) standard cystoscopy with saline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ureteral Jet Visibility</measure>
    <time_frame>5 minutes</time_frame>
    <description>Surgeons will chose from a likert scales as either:
not visible
Somewhat visible
clearly visible This will be completed during the cystoscopic evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgeon Satisfaction</measure>
    <time_frame>5 mins</time_frame>
    <description>A 4 point likert scale will be completed during the procedure to assess satisfaction as follows:
very satisfied
satisfied
somewhat satisfied
unacceptable</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Urinary Tract Infections</measure>
    <time_frame>6 weeks</time_frame>
    <description>Medical records will be followed prospectively for 6 weeks to assess for incidence of urinary tract infections within different groups.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Injury of Ureter</condition>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infused into the bladder to allow for visualization of bladder walls and urine jets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextrose 10%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infused into the bladder to allow for visualization of bladder walls and colored urine jets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenazopyridine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will be administered (orally) preoperatively and will be evaluated for its colorization properties during cystoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Fluorescein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will be administered (intravenously) prior to the cystoscopy and will be evaluated for its colorization properties during cystoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Used to distend the bladder for cystoscopic evaluation</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <other_name>Saline</other_name>
    <other_name>NS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenazopyridine</intervention_name>
    <description>Administered orally preoperatively and assessed during cystoscopy</description>
    <arm_group_label>Phenazopyridine</arm_group_label>
    <other_name>Pyridium</other_name>
    <other_name>AZO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextrose 10%</intervention_name>
    <description>Used to distend the bladder for cystoscopic evaluation</description>
    <arm_group_label>Dextrose 10%</arm_group_label>
    <other_name>D10</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Fluorescein</intervention_name>
    <description>Administered intravenously and assessed during cystoscopy</description>
    <arm_group_label>Sodium Fluorescein</arm_group_label>
    <other_name>Fluorescein</other_name>
    <other_name>Fluorocyte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult

          -  undergoing a cystoscopy or as part of their planned procedure

        Exclusion Criteria:

          -  Chronic kidney disease

          -  known prior surgical removal of kidney or ureteral obstruction

          -  Current ureteral stent placed

          -  Allergy to any of the interventions
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Davila, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cleveland Clinic Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandriah Alas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cleveland Clinic Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis M Espaillat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric A Hurtado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>June 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2015</study_first_posted>
  <results_first_submitted>August 22, 2018</results_first_submitted>
  <results_first_submitted_qc>October 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 23, 2019</results_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cleveland Clinic Florida</investigator_affiliation>
    <investigator_full_name>Cecilia Calvo</investigator_full_name>
    <investigator_title>Quality Assurance</investigator_title>
  </responsible_party>
  <keyword>ureteral jet</keyword>
  <keyword>pelvic surgery</keyword>
  <keyword>cystoscopy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Normal Saline</title>
          <description>Infused into the bladder to allow for visualization of bladder walls and urine jets.
Normal saline: Used to distend the bladder for cystoscopic evaluation</description>
        </group>
        <group group_id="P2">
          <title>Dextrose 10%</title>
          <description>Infused into the bladder to allow for visualization of bladder walls and colored urine jets.
Dextrose 10%: Used to distend the bladder for cystoscopic evaluation</description>
        </group>
        <group group_id="P3">
          <title>Phenazopyridine</title>
          <description>Will be administered (PO) preoperatively and will be evaluated for its colorization properties during cystoscopy.
Phenazopyridine: Administered orally preoperatively and assessed during cystoscopy</description>
        </group>
        <group group_id="P4">
          <title>Sodium Fluorescein</title>
          <description>Will be administered (IV) prior to the cystoscopy and will be evaluated for its colorization properties during cystoscopy.
Sodium Fluorescein: Administered intravenously and assessed during cystoscopy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44">one given phenazopyridine pre-op and was analyzed in her randomization group per intention to treat</participants>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Normal Saline</title>
          <description>Infused into the bladder to allow for visualization of bladder walls and urine jets.
Normal saline: Used to distend the bladder for cystoscopic evaluation</description>
        </group>
        <group group_id="B2">
          <title>Dextrose 10%</title>
          <description>Infused into the bladder to allow for visualization of bladder walls and colored urine jets.
Dextrose 10%: Used to distend the bladder for cystoscopic evaluation</description>
        </group>
        <group group_id="B3">
          <title>Phenazopyridine</title>
          <description>Will be administered (PO) preoperatively and will be evaluated for its colorization properties during cystoscopy.
Phenazopyridine: Administered orally preoperatively and assessed during cystoscopy</description>
        </group>
        <group group_id="B4">
          <title>Sodium Fluorescein</title>
          <description>Will be administered (IV) prior to the cystoscopy and will be evaluated for its colorization properties during cystoscopy.
Sodium Fluorescein: Administered intravenously and assessed during cystoscopy</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="44"/>
            <count group_id="B4" value="44"/>
            <count group_id="B5" value="176"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="44"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="44"/>
                    <count group_id="B4" value="44"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="13.8"/>
                    <measurement group_id="B2" value="59.3" spread="12.1"/>
                    <measurement group_id="B3" value="60" spread="9.7"/>
                    <measurement group_id="B4" value="60.3" spread="13.9"/>
                    <measurement group_id="B5" value="60.7" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="44"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="44"/>
                    <count group_id="B4" value="44"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="176"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="44"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="44"/>
                    <count group_id="B4" value="44"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.4" lower_limit="19.8" upper_limit="38.9"/>
                    <measurement group_id="B2" value="26.9" lower_limit="22.1" upper_limit="38.8"/>
                    <measurement group_id="B3" value="30.3" lower_limit="21.6" upper_limit="41.0"/>
                    <measurement group_id="B4" value="26.7" lower_limit="20.6" upper_limit="42"/>
                    <measurement group_id="B5" value="27.6" lower_limit="19.8" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ureteral Jet Visibility</title>
        <description>Surgeons will chose from a likert scales as either:
not visible
Somewhat visible
clearly visible This will be completed during the cystoscopic evaluation</description>
        <time_frame>5 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline</title>
            <description>Infused into the bladder to allow for visualization of bladder walls and urine jets.
Normal saline: Used to distend the bladder for cystoscopic evaluation</description>
          </group>
          <group group_id="O2">
            <title>Dextrose 10%</title>
            <description>Infused into the bladder to allow for visualization of bladder walls and colored urine jets.
Dextrose 10%: Used to distend the bladder for cystoscopic evaluation</description>
          </group>
          <group group_id="O3">
            <title>Phenazopyridine</title>
            <description>Will be administered (PO) preoperatively and will be evaluated for its colorization properties during cystoscopy.
Phenazopyridine: Administered orally preoperatively and assessed during cystoscopy</description>
          </group>
          <group group_id="O4">
            <title>Sodium Fluorescein</title>
            <description>Will be administered (IV) prior to the cystoscopy and will be evaluated for its colorization properties during cystoscopy.
Sodium Fluorescein: Administered intravenously and assessed during cystoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Ureteral Jet Visibility</title>
          <description>Surgeons will chose from a likert scales as either:
not visible
Somewhat visible
clearly visible This will be completed during the cystoscopic evaluation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Clearly Visible</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Somewhat Visible</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Visible</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgeon Satisfaction</title>
        <description>A 4 point likert scale will be completed during the procedure to assess satisfaction as follows:
very satisfied
satisfied
somewhat satisfied
unacceptable</description>
        <time_frame>5 mins</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline</title>
            <description>Infused into the bladder to allow for visualization of bladder walls and urine jets.
Normal saline: Used to distend the bladder for cystoscopic evaluation</description>
          </group>
          <group group_id="O2">
            <title>Dextrose 10%</title>
            <description>Infused into the bladder to allow for visualization of bladder walls and colored urine jets.
Dextrose 10%: Used to distend the bladder for cystoscopic evaluation</description>
          </group>
          <group group_id="O3">
            <title>Phenazopyridine</title>
            <description>Will be administered (PO) preoperatively and will be evaluated for its colorization properties during cystoscopy.
Phenazopyridine: Administered orally preoperatively and assessed during cystoscopy</description>
          </group>
          <group group_id="O4">
            <title>Sodium Fluorescein</title>
            <description>Will be administered (IV) prior to the cystoscopy and will be evaluated for its colorization properties during cystoscopy.
Sodium Fluorescein: Administered intravenously and assessed during cystoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Surgeon Satisfaction</title>
          <description>A 4 point likert scale will be completed during the procedure to assess satisfaction as follows:
very satisfied
satisfied
somewhat satisfied
unacceptable</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Very Satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Somewhat Satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unacceptable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Urinary Tract Infections</title>
        <description>Medical records will be followed prospectively for 6 weeks to assess for incidence of urinary tract infections within different groups.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline</title>
            <description>Infused into the bladder to allow for visualization of bladder walls and urine jets.
Normal saline: Used to distend the bladder for cystoscopic evaluation</description>
          </group>
          <group group_id="O2">
            <title>Dextrose 10%</title>
            <description>Infused into the bladder to allow for visualization of bladder walls and colored urine jets.
Dextrose 10%: Used to distend the bladder for cystoscopic evaluation</description>
          </group>
          <group group_id="O3">
            <title>Phenazopyridine</title>
            <description>Will be administered (PO) preoperatively and will be evaluated for its colorization properties during cystoscopy.
Phenazopyridine: Administered orally preoperatively and assessed during cystoscopy</description>
          </group>
          <group group_id="O4">
            <title>Sodium Fluorescein</title>
            <description>Will be administered (IV) prior to the cystoscopy and will be evaluated for its colorization properties during cystoscopy.
Sodium Fluorescein: Administered intravenously and assessed during cystoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Urinary Tract Infections</title>
          <description>Medical records will be followed prospectively for 6 weeks to assess for incidence of urinary tract infections within different groups.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Normal Saline</title>
          <description>Infused into the bladder to allow for visualization of bladder walls and urine jets.
Normal saline: Used to distend the bladder for cystoscopic evaluation</description>
        </group>
        <group group_id="E2">
          <title>Dextrose 10%</title>
          <description>Infused into the bladder to allow for visualization of bladder walls and colored urine jets.
Dextrose 10%: Used to distend the bladder for cystoscopic evaluation</description>
        </group>
        <group group_id="E3">
          <title>Phenazopyridine</title>
          <description>Will be administered (PO) preoperatively and will be evaluated for its colorization properties during cystoscopy.
Phenazopyridine: Administered orally preoperatively and assessed during cystoscopy</description>
        </group>
        <group group_id="E4">
          <title>Sodium Fluorescein</title>
          <description>Will be administered (IV) prior to the cystoscopy and will be evaluated for its colorization properties during cystoscopy.
Sodium Fluorescein: Administered intravenously and assessed during cystoscopy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated blood pressure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>parathesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Post-op retention</sub_title>
                <description>W/ bladder rupture POD#4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Weaknesses include that without any postoperative diagnoses of ureteral injury, we cannot comment on the sensitivity or specificity of each method.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Eric Hurtado</name_or_title>
      <organization>Cleveland Clinic Florida</organization>
      <phone>954-659-5559</phone>
      <email>hurtade@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

